It's tricky when it's a product that requires vast, expensive R&D - but is easy to copy.
Pharmaceuticals is an obvious example.
Complain about profiteering all you like, but drugs companies get a narrow window of several years between the drug coming to market and the patent expiring, within which to recoup their costs.
And those profits have to compensate for the large number of drugs that swallow a lot of R&D costs and never make it to market.
Remove that profit and they have no incentive to continue innovating.